Genetic Polymorphisms in CYP2 Gene Family in Bulgarian Individuals and their Clinical Implications
DOI:
https://doi.org/10.2478/amb-2024-0001Keywords:
drug safety, pharmacogenetics, genetic polymorphisms, cytochrome P450Abstract
The cytochrome P450 superfamily consists of hemeproteins involved in the detoxication of different xenobiotics, including drugs. The CYP2 gene family is responsible for the metabolism of 80% of the drugs in clinical use. There are considerable interindividual
and interethnic variabilities in the rate of drug metabolism as a result of genetic polymorphisms. The goal of our study was to determine the frequency of 10 genetic polymorphisms in CYP2 family genes to give light on the pharmacogenetic defects of the main CYPs, involved in drug metabolism, in Bulgarian individuals. We detected high allele frequency for CYP2D6*10 (0.27), CYP2D6*4 (0.22), and CYP2B6*9 (0.24), followed by CYP2C19*2 (0.14), CYP2C9*3 (0.11) and CYP2C9*2 (0.09). The genotype frequencies were also determined for all investigated variants. In total 47.2% of the analyzed individuals carried CYP2D6 genetic polymorphisms – 5.6% carried a single variant and 41.6% were found to have two or more such variants. Homozygotes for CYP2D6 variants were established
among 14% of Bulgarian individuals. Determination of the prevailing pharmacogenetic polymorphisms of the CYPs, most responsible for drug metabolism, will lead to a lower risk of drug toxicity, increased drug efficacy, and drug dose optimization.
References
Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current Drug Targets. 2018; 19(1):38-54.
Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 2010; 69(3):222-230.
Zhao M, Ma J, Li M et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci. 2021; 22(23):12808.
Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.
Naunyn-Schmiedeberg’s Archives of Pharmacology. 2004; 369(1):89-104.
Dorji PW, Tshering G, Na-Bangchang K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. J Clin Pharm Ther. 2019; 44:508-524
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2):229-243.
Hassani Idrissi H, Hmimech W, Khorb NE, et al. A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function
and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. BMC Research Notes. 2018; 11(1):46.
Brown SA, Pereira N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. J. Pers. Med. 2018; 8(1):8.
Riaz S, Muhammad Din S, Usman Tareen M, et al. Genetic Polymorphism of CYP2C19 in Pakistani Population. Iran J Pharm Res. 2019; 18(2):1097-1102.
Ivanov HY, Grigorova D, Lauschke VM, et al. CYP2C19, and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort. J Pers Med. 2022 Jul 21; 12(7):1187
Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 2000; 10(6):567-570.
Mo SL, Liu YH, Duan W, et al. Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6. Current Drug Metabolism. 2009; 10(7):730-753.
Langmia IM, Just KS, Yamoune S, et al. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations – Implication for Drug Safety, Dosing, and Individualized Therapy. Frontiers in Genetics. 2021; 12.
Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and Genomics. 2005; 15(1):1-5.
Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol 2013; 69(11):1909-1916.
Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Frontiers in Genetics. 2013; 4.
Victorri-Vigneau C, Verstuyft C, Bouquié R, et al. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Br J Clin Pharmacol 2019; 85(7):1538-1543.
Chiang YC, Wang RY, Huang CL, et al. Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction. J Cell Mol Med .2017; 21(12):3552-3564.
Aghabozorg Afjeh SS, Boshehri B, Hamednia S, et al. Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran. Iranian Biomedical Journal. 2021; 25(3):220-225.
Kharasch ED, Regina KJ, Blood J, et al. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology. 2015; 123(5):1142-1153.
Dean L, Kane M. Clopidogrel Therapy and CYP2C19 Genotype. 2012 Mar 8 [updated 2022 Dec 1]. In: Pratt VM, Scott SA, Pirmohamed M, et al. editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012
Alrajeh KY, Roman YM. The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. Personalized Medicine. 2022; 19(4):327-339.
Shuldiner AR, O‘Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26; 302(8):849-857
Wang B, Wang J, Huang SQ, et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Current Drug Metabolism. 2009; 10(7):781-834.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 S. Yovinska, D. Bakalov, K. Mihova, K. Kamenarova, R. Kaneva, R. Nikolov, I. Dimova (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
